Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

By D. Ross, S. Branford, J. Seymour, A. Schwarer, C. Arthur, D. Yeung, P. Dang, J. Goyne, C. Slader, R. Filshie and 5 more. Blood, 2013

706 citations recorded by the source corpus.